PARIS (BUSINESS WIRE) Regulatory News:Onxeo S.A. (Euronext Growth: ALONX, Nasdaq First North1: ONXEO), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR)n in particular against rare or resistant forms of cancer, today announced that.
Regulatory News: Onxeo S.A. (Euronext Growth: ALONX, Nasdaq First North1: ONXEO), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage
Last day of trading on the First North Growth market on November 8, 2022 Listing on Euronext Growth Paris remains unchanged Regulatory News: Onxeo S.A. (Euronext Growth: ALONX, Nasdaq
Onxeo Announces That Nasdaq Approved the Delisting of Its Shares From the First North Growth Market in Copenhagen streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.